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ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, whose etiology is unknown, and 
which is characteristic by the appearance of a diverse neurological symptomatology consisting of outbreaks or gradual 
deterioration and lesions in any location of the brain’s white matter which may provoke the after-effect of a definitive 
demyelination of the area.
The disease affects young people, with its appearance being most frequent between 20 and 40 years of age, in temperate 
and cold climates, and with a man-woman rate of 0.46 / 0.67.
The magnitude of this disease lies in the fact that it is the primary cause for permanent disablement among young adults.
We are presenting 4 cases of MS whose initial symptom of the disease was the appearance of paraesthesia in the maxillofacial 
area, affecting one or more ramifications of the trigeminal nerve, and a progression time varying from 15 days to one year.
All the patients were clinically diagnosed, with their diagnostics being confirmed both with magnetic resonance imaging 
as well as through the study of their cerebrospinal fluid (CSF) and the evoked potentials (EPs).
Manifestations in the oral and facial area were the first manifestation of the disease in all cases.
Key words: Facial paraesthesia, multiple sclerosis.
RESUMEN
La esclerosis múltiple (EM) es una enfermedad inflamatoria crónica del sistema nervioso central  de etiología no conocida 
caracterizada por la aparición de sintomatologia neurológica diversa en forma de brotes o de deterioro progresivo y de 
lesiones en cualquier localización de la sustancia blanca cerebral que pueden dejar como secuelas la desmielinización 
definitiva de la zona.
Esta enfermedad afecta a gente joven siendo más frecuente su aparición entre los 20 y 40 años, en climas templados y 
fríos y con una relación hombre-mujer de 0,46 / 0,67.
La importancia de esta enfermedad radica en que es la primera causa de invalidez permanente en adultos jóvenes.
Presentamos 4 casos de  EM cuyo síntoma de inicio de la enfermedad fue la aparición de parestesias en el territorio maxi-
lo-facial afectando a una o más ramas del trigémino y de tiempo de evolución que oscilaba entre 15 días y un año.
Todos los pacientes fueron diagnosticados clínicamente siendo confirmado el diagnostico, tanto con la resonancia mag-
nética como con el estudio del liquido cefalorraquídeo (LC) y los potenciales evocados(PE).
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Las manifestaciones en el territorio oral y facial fueron la primera manifestación de la enfermedad en todos los casos.
Palabras clave: Parestesia facial, esclerosis múltiple.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease 
of  the central nervous system (CNS), whose etiology is 
unknown and which may be caused by multiple factors, 
and it is thought that a genetic predisposition together 
with immunity and environmental factors could trigger 
the disease. (1,2)
MS is a disease affecting young people. It appears most 
frequently among individuals from 20 to 40 years old, at 
intervals of 10 to 60 years. It affects more women than men, 
in a proportion of 0.67 /0.46, and it occurs in cold and warm 
climates. In the world distribution of  the disease, Spain 
ranks among the countries with a high frequency and pre-
valence, with a rate, varying depending on studies, between 
15-25 patients every 100,000 inhabitants. (3,4)
MS represents a complex clinic alteration, presenting a 
highly diverse symptomatology as a result of the demye-
lination of  the CNS, and a later slow down or blocked 
transmission at the level of axons. Ectopic impulses may 
also appear, providing positive signs (paroxysms, convulsio-
ns). The combination of these negative and positive signs 
inform the base of its great variability and variegated clinic 
symptomatology. (5,6)
Given its progression in outbreaks or in the form of gra-
dual deterioration, and in order to be able to assess its 
clinic severity, MS has been internationally classified in 4 
subtypes.-
1. -Relapsing–Remitting (RR). 2- Progressive-Relapsing 
(PR). 3. - Secondary-Progressive (SP) .4. - Primary-Pro-
gressive (PP).
RR is the most frequent form of  presentation of  MS, 
accounting for 85% of cases. This clinic subtype is cha-
racterized by the appearance of outbreaks resolved with 
or without sequelae, interspersed with periods of  clinic 
stability. These patients may remain 10 –15 years in a more 
or less stable condition, before progressing towards SP, with 
the progress of the disease in that clinic form being slow. 
On the contrary, in 15% of cases the disease presents a 
progressive (PR) or sharp (PP) progress from its inception. 
In those cases the disease does not progress in outbreaks, 
and from the very beginning there are acute relapses with 
occasional stabilizations and less and less improvements, 
with a quick progress towards disability and therefore with 
a worse prognosis. (1,5)
Clinically MS usually appears with a number of symptoms 
of  neurological anomalies which settle in a mater of 
minutes or hours, and which frequently progress in later 
days, where the most frequent are: visual and oculomotor 
anomalies (49 %)  - optical neuritis, anterior internuclear 
ophthalmic paralysis. Palsies (43%) in the form of partial 
or incomplete palsies, locomotor weakness, clumsiness in 
hands, etc. Paraesthesia (41%) that is, alteration of feeling 
such as numbness of arms, legs, face, etc. Signs of lack of 
motor coordination (23%), or tonic spasms. Genito-urinary 
dysfunction (10%), urination urge, increase of  urination 
frequency, lack of bladder control and episodic retention 
of urine. Signs of brain damage (4%) such as paroxysmal 
ataxia and dysarthria or shaking of upper limbs. (5,6)
Once the disease has settled, the signs of neurological ano-
maly are usually coupled with paroxysmal alterations, such 
as tonic spasms and involuntary movements, nystagmus, 
trigeminal neuralgia, episodic dysarthria, ataxia, episodes 
of intense itching, etc lasting minutes or even seconds, and 
which lead us to catalogue patients as suffering from anxiety 
or even hysteria. (1,5-7)
MS is a disease difficult to diagnose given its variable 
forms of  presentation and symptomatology. Therefore, 
progress in image diagnostic techniques has been crucial 
when it comes to accurate diagnostics. MS diagnostic is 
still clinical, although cranial and spinal studies through 
magnetic resonance imaging (MRI), evoked potentials and 
the analysis of the cerebrospinal fluid (CSF) are the main 
diagnostic exploration used for the confirmation of clinical 
data. (1,7,8)
Currently, the criteria followed for a definite diagnostic of 
MS are based on the confirmation of its progression in time 
and space, of its symptoms and signs. These criteria were 
developed by a committee of neurologists and published in 
2001 by McDonald et al (9), who based their work on the 
magnetic resonance MS diagnostic criteria. (1,8-10) 
The progress and prognosis of  MS are not predictable. 
However, there are certain criteria which may lead us to 
a worse prognosis, namely: an advanced age at the appea-
rance of the disease, being a male, the initial cerebellar or 
motor clinical study, the number of outbreaks in the first 
two years, the brief  time interval between them, or family 
history.(11).
There are three goals in the treatment of MS: to shorten the 
duration of the outbreak, to alter the natural progress of the 
disease, and to reduce it to a symptomatic condition.
The treatment of the outbreaks has the goal of reducing the 
duration of relapses, an improvement of symptoms, and a 
prevention of complication. Treatment requires the use of 
steroids either orally or by pulses of methylprednisolone 
of 1000mg IV / day. 
The immunomodulatory treatment, aimed at preventing 
the progress of the disease, differs depending on the various 
progressive forms of MS, with Betaferon being the most 
effective in the RR forms, and symptomatic treatment aimed 
at improving the quality of life of these young patients by 
reducing their symptoms and attempting to minimize their 
disabilities. (1,12,13).
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Casos 1 2 3 4 
Edad 44 años 46 años 54 años 27 años 
Sexo Varón Mujer Mujer Mujer 
Primera manifestación 
Adormecimiento en 










Disestesias en maxilar 
inferior izquierdo y 
superior derecho. 
Localización 2ª y 3 ª rama trigémino derecho 
2ª y 3 ª rama 
trigémino derecho 
2ª rama trigémino 
izquierda
2ª y 3 ª rama trigémino 
derecho e izquierdo. 
Tiempo evolución 15 días 6 meses 1 año 1 año 












en actividad en sustancia 
blanca periventricular 
derecha  y pedúnculo 
cerebeloso. 
Fig. 1. Clinic exploration of case nº. 2.-dysesthesia in commissure 
of the lips with an evolution of 6 months
Fig. 2. MRI of case nº. 2.- Multiple periventricular 
demyelinating images
Table 1. Clinical features of the four cases.
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CLINICAL TRIALS
The reason for this work is the presentation of 4 clinic cases of 
MS whose first manifestations were in the maxillofacial area.
The clinical cases of the four cases of MS presented by us 
included in table 1, with the patients having been visited in 
the Stomatology and Neurology Departments of the Hos-
pital General Universitario of Valencia throughout 2004.
Our patients were 3 women and one men, aged between 27 
and 54. All of them described an initial symptomatology 
of the appearance of tingling sensations, numbness, strange 
sensations in their faces affecting one or more ramifications 
of the trigeminal nerve, the most frequent being the second 
and third ramification, lasting in time although varying in 
intensity.
The male patient (case 1), who went to the department as 
soon as the first symptoms appeared, was developing his 
first outbreak. A multiplicity of neurological manifestations 
gradually appeared and made his hospitalisation necessary. 
On the contrary, the beginning of the three other cases was 
much more insidious, for the disease manifested itself  only 
through paraesthesias, with the effect that the patients de-
layed reporting to the clinic. In case 4, the patient suffered 
from dysesthesias, that is, sensorial deficits coinciding with 
neuralgic pains spontaneously appearing and disappea-
ring, without a complete disappearance of the symptoms. 
Throughout the course of the last year, the patient has had 
a severe outbreak with a feeling of dizziness, instability in 
walking, general discomfort, nauseas and vomits, requiring 
hospitalisation.
In all cases, given the clinical conjecture (fig. 1), MRI was 
carried out (fig. 2), a study of the CSF and of the visual, 
auditory and bodysensorial evoked potentials in order to be 
able to confirm the disease. In all of them, the MRI shows 
the characteristic demyelination in different locations of the 
white matter, with the CSF positive in cases 1 and 4, and 
positive evoked potentials in case 4, all of them meeting the 
diagnostic criteria set by Mc Donald et al (9).
DISCUSSION
As we have already said, MS is a disease characterized by 
the appearance of multiple neurological symptomatology. 
Therefore, the appearance of  PARAESTHESIAS in the 
oral and facial area is an ALARMING SYMPTOM which 
should made us suspicious of the existence of a possible 
neurological problem, something that would force us to fo-
cus our intervention on an early diagnostic after a thorough 
clinical exploration aimed at discarding any either local or 
general iatrogenic pathology which could be responsible 
for the hypoesthesia. Subsequently, we must complete our 
diagnose with MRI and an assessment by the neurological 
department aimed at confirming the MS.(1-5)
An early diagnosis is critical in the prognosis of the disease 
(11) because, as we have already pointed out, it is an inflam-
matory process which, when it becomes chronic, leads to the 
definitive demyelization of the area. If there is a treatment in 
the early stages of the process consisting of the suppression 
of the inflammatory outbreaks, we will be directly acting 
on the development of the disease and therefore improving 
the patients’ quality of life (12-13). Diagnosis is not always 
easy, for MS is normally considered when an optic neuritis 
or a diplopia appears in a young adult. However, it is hard 
to imagine that such a serious neurological process is behind 
facial paraesthesias, and it is easier to label these patients 
as suffering from anxiety, depression or from a temporo-
mandibular joint pathology or muscle contracture. Some-
times they are classified as atypical facial pain (2,14), and 
are usually patients who, on arriving at our practice, have 
already seen other professionals and followed a number of 
ineffective treatments. Therefore, we ought to consider the 
progression time as longer than what we are being told and 
that our quick diagnosis will improve the possible quality 
of life of those patients.
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